So you'd think being CEO of multi-billion-dollar consumer electronics powerhouse Apple would provide more than enough of the good stuff to ward off unwanted illness.
Yet investors were unconvinced after speculation grew on the causes of Steve Jobs' dramatic weight loss after a product launch last year.
Yesterday, Jobs finally (and reluctantly) penned a letter acknowledging speculation about his health and dispelling rumors he was on his 'deathbed' or even that there were any immediate plans to step down as Apple chief.
Investors welcomed Jobs' frank submission, rewarding its share price with a 4.2 percent rise in New York. The share price spike was a clear testimony to investors' high regard for Jobs, the man many credit with turning around the electronics manufacturer.
The focus for any firm in Apple's position should be succession planning. While having a demigod in charge is all very well, it leaves open the question of what will happen in the long term. Is he or she the lone genius in an otherwise distinctly average management team? Will a sudden and unexpected departure destroy the intricate balance of chemistry on the board?
The fortunate consequence of Jobs' recent absence has been the chance for other members of the management team to share a piece of the limelight. It is just a shame that Apple and Jobs, in particular, were so cagey about acknowledging the questions surrounding his health. A CEO may be entitled to a private life but where health is concerned, investors have a right to know where they stand. The absence of any communication only served to exacerbate the whisperings and amplify the dissenting voices.
Deputy international editor